Mechanisms of Stem Cells and Their Secreted Exosomes in the Treatment of Autoimmune Diseases

Overview

Journal Curr Stem Cell Res Ther

Publisher Bentham Science Publishers

Specialties Cell Biology
Pharmacology

Date 2024 Feb 5

PMID 38311916

Authors

Shu-Qian Lin

Kai Wang

Xing-Hua Pan

Guang-Ping Ruan

Affiliations

Soon will be listed here.

Abstract

Stem cells play a therapeutic role in many diseases by virtue of their strong self-renewal and differentiation abilities, especially in the treatment of autoimmune diseases. At present, the mechanism of the stem cell treatment of autoimmune diseases mainly relies on their immune regulation ability, regulating the number and function of auxiliary cells, anti-inflammatory factors and proinflammatory factors in patients to reduce inflammation. On the other hand, the stem cell- derived secretory body has weak immunogenicity and low molecular weight, can target the site of injury, and can extend the length of its active time in the patient after combining it with the composite material. Therefore, the role of secretory bodies in the stem cell treatment of autoimmune diseases is increasingly important.

References

Liu G, David B, Trawczynski M, Fessler R . Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. Stem Cell Rev Rep. 2019; 16(1):3-32. PMC: 6987053. DOI: 10.1007/s12015-019-09935-x. View

Caplan A . Mesenchymal Stem Cells: Time to Change the Name!. Stem Cells Transl Med. 2017; 6(6):1445-1451. PMC: 5689741. DOI: 10.1002/sctm.17-0051. View

Tsiapalis D, ODriscoll L . Mesenchymal Stem Cell Derived Extracellular Vesicles for Tissue Engineering and Regenerative Medicine Applications. Cells. 2020; 9(4). PMC: 7226943. DOI: 10.3390/cells9040991. View

Wigerblad G, Kaplan M . Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. 2022; 23(5):274-288. PMC: 9579530. DOI: 10.1038/s41577-022-00787-0. View

He J, Chen J, Miao M, Zhang R, Cheng G, Wang Y . Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2022; 5(11):e2241451. PMC: 9650609. DOI: 10.1001/jamanetworkopen.2022.41451. View

Zhang P, Dong B, Yuan P, Li X . Human umbilical cord mesenchymal stem cells promoting knee joint chondrogenesis for the treatment of knee osteoarthritis: a systematic review. J Orthop Surg Res. 2023; 18(1):639. PMC: 10466768. DOI: 10.1186/s13018-023-04131-7. View

Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, Ghasemi A, Poursamimi J, Mohammadi M . Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran. Biomed Pharmacother. 2018; 109:1834-1840. DOI: 10.1016/j.biopha.2018.11.056. View

Grigoriou M, Banos A, Filia A, Pavlidis P, Giannouli S, Karali V . Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus. Ann Rheum Dis. 2019; 79(2):242-253. PMC: 7025734. DOI: 10.1136/annrheumdis-2019-215782. View

Jaime-Perez J, Gonzalez-Trevino M, Melendez-Flores J, Ramos-Davila E, Cantu-Rodriguez O, Gutierrez-Aguirre C . Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort. Clin Rheumatol. 2021; 41(3):869-876. DOI: 10.1007/s10067-021-05931-0. View

10.

Jalalvand M, Enayati S, Akhtari M, Madreseh E, Jamshidi A, Farhadi E . Blood regulatory T cells in inflammatory bowel disease, a systematic review, and meta-analysis. Int Immunopharmacol. 2023; 117:109824. DOI: 10.1016/j.intimp.2023.109824. View

11.

Silva T, Alencar R, de Souza Silva B, Viana E, Fragoso Y, Gomes A . Effect of photobiomodulation on fatigue in individuals with relapsing-remitting multiple sclerosis: a pilot study. Lasers Med Sci. 2022; 37(8):3107-3113. DOI: 10.1007/s10103-022-03567-3. View

12.

van Rampelbergh J, Achenbach P, Leslie R, Ali M, Dayan C, Keymeulen B . First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes. BMC Med. 2023; 21(1):190. PMC: 10210318. DOI: 10.1186/s12916-023-02900-z. View

13.

Shan J, Jin H, Xu Y . T Cell Metabolism: A New Perspective on Th17/Treg Cell Imbalance in Systemic Lupus Erythematosus. Front Immunol. 2020; 11:1027. PMC: 7257669. DOI: 10.3389/fimmu.2020.01027. View

14.

Zhou C, Bai X, Yang Y, Shi M, Bai X . Single-Cell Sequencing Informs That Mesenchymal Stem Cell Alleviates Renal Injury Through Regulating Kidney Regional Immunity in Lupus Nephritis. Stem Cells Dev. 2023; 32(15-16):465-483. DOI: 10.1089/scd.2023.0047. View

15.

Geng L, Tang X, Wang S, Sun Y, Wang D, Tsao B . Reduced Let-7f in Bone Marrow-Derived Mesenchymal Stem Cells Triggers Treg/Th17 Imbalance in Patients With Systemic Lupus Erythematosus. Front Immunol. 2020; 11:233. PMC: 7040072. DOI: 10.3389/fimmu.2020.00233. View

16.

Geng L, Sun L . MicroRNAs in mesenchymal stem cells: the key to decoding systemic lupus erythematosus. Cell Mol Immunol. 2021; 18(9):2286-2287. PMC: 8429566. DOI: 10.1038/s41423-021-00722-8. View

17.

Li W, Chen W, Sun L . An Update for Mesenchymal Stem Cell Therapy in Lupus Nephritis. Kidney Dis (Basel). 2021; 7(2):79-89. PMC: 8010225. DOI: 10.1159/000513741. View

18.

Cheng T, Ding S, Liu S, Li Y, Sun L . Human umbilical cord-derived mesenchymal stem cell therapy ameliorates lupus through increasing CD4+ T cell senescence via MiR-199a-5p/Sirt1/p53 axis. Theranostics. 2021; 11(2):893-905. PMC: 7738872. DOI: 10.7150/thno.48080. View

19.

Gao L, OConnell M, Allen M, Liesveld J, McDavid A, Anolik J . Bone marrow mesenchymal stem cells from patients with SLE maintain an interferon signature during in vitro culture. Cytokine. 2019; 132:154725. DOI: 10.1016/j.cyto.2019.05.012. View

20.

Wei S, Xie S, Yang Z, Peng X, Gong L, Zhao K . Allogeneic adipose-derived stem cells suppress mTORC1 pathway in a murine model of systemic lupus erythematosus. Lupus. 2018; 28(2):199-209. DOI: 10.1177/0961203318819131. View